Ocugen, Inc. (NASDAQ:OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy.
• Ocugen stock is taking a hit today. What’s weighing on OCGN shares?
The stock’s decline comes as the broader market is experiencing gains, with major indices such as the S&P 500 up 0.64% and the Nasdaq gaining 1.07%.
Ocugen’s Phase 2 Trial Shows 46% Lesion Reduction
Preliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion growth compared to the control group after 12 months, with no serious adverse events reported across both phase 1 and phase 2 trials.
The medium dose of OCU410 achieved a 54% reduction in lesion size, while the high dose showed a 36% reduction, highlighting the therapy’s potential efficacy.
The company said in the context of geographic atrophy, which affects millions worldwide, the findings suggest a promising alternative to current treatments that require frequent injections.
The company plans to report full data from the phase 2 trial later this quarter and initiate a phase 3 trial in 2026.
Ocugen remains on track for a Biologics License Application (BLA) filing for OCU410 in 2028.
Other Programs
On Monday, Ocugen announced the publication of phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye.
The publication reports comprehensive 12-month safety, tolerability and exploratory efficacy data from the first-in-human Phase 1 trial evaluating OCU410ST in patients with early to advanced Stargardt disease.
The Phase 1 GARDian1 trial demonstrated robust efficacy and safety outcomes supporting the clinical development of OCU410ST.
In September 2025, Ocugen inked a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, its modifier gene therapy for retinitis pigmentosa.
OCGN Shows Bullish Momentum; RSI at 71
The stock is currently trading 15.2% above its 20-day simple moving average (SMA) and 28% above its 50-day SMA, demonstrating strength in the short term. Over the past 12 months, shares have increased 138.56% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 71, indicating that the stock is in overbought territory, while the MACD is above its signal line, suggesting bullish momentum. The combination of an overbought RSI and bullish MACD signals indicates strong buying interest but may also suggest a potential pullback if profit-taking occurs.
- Key Resistance: $1.96
- Key Support: N/A
OCGN Price Action
OCGN Price Action: Ocugen shares were down 9.08% at $1.71 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: PeopleImages.com – Yuri A on Shutterstock
Recent Comments